Entera Bio Ltd.
ENTXNasdaq
$1.98
↓ -1.0%Jul 17 close · end-of-day
Price
1Y↓ -2.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$94.6M
Enterprise Value
$90.4M
P/E
7.6
P/S
—
P/B
8.8
EV/EBITDA
—
PEG
—
FCF Yield
-9.7%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$12.4M
Free Cash Flow (TTM)
-$9.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-115.8%
ROIC
-150.8%
Debt / Equity
—
Net Cash
$4.1M
Return 1Y
-2.9%
Company profile
Entera Bio Ltd. focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism.
- CEO
- Miranda J. Toledano
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Website
- enterabio.com
Management & directors
- Toledano Miranda JayneChief Executive Officer
- Burshtein GregoryChief of R&D
- Galitzer HillelChief Operating Officer
- Yaacov-Garbeli DanaChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
ENTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS$0.07↑ +16.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $365,000.00 | $571,000.00 | $134,000.00 | $0.00 | $181,000.00 | $42,000.00 |
| Gross profit | $65,000.00 | $198,000.00 | $33,000.00 | $0.00 | $9,000.00 | $0.00 |
| Operating income | -$11.2M | -$12.2M | -$13.0M | -$8.9M | -$9.6M | -$11.5M |
| Net income | -$11.2M | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M |
| Diluted EPS | — | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Operating cash flow | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.4M |
| Free cash flow | -$10.6M | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M |
| Gross margin | 17.8% | 34.7% | 24.6% | — | 5.0% | 0.0% |
| Operating margin | -3059.7% | -2139.6% | -9714.2% | — | -5295.6% | -27450.0% |
| Net margin | -3072.9% | -2134.3% | -9754.5% | — | -5271.3% | -27235.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57,000.00 | $42,000.00 | $82,000.00 | $42,000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $9,000.00 | $0.00 | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$2.2M | -$3.0M | -$2.3M | -$2.6M | -$2.7M | -$3.3M | -$3.0M | -$3.5M |
| Net income | -$2.1M | -$3.0M | -$2.4M | -$2.6M | -$2.7M | -$3.2M | -$3.0M | -$3.5M |
| Diluted EPS | $0.06 | $0.08 | $0.06 | $0.06 | $0.06 | $0.07 | $0.06 | $0.07 |
| Operating cash flow | -$1.3M | -$2.2M | -$1.5M | -$1.4M | -$1.6M | -$2.5M | -$1.8M | -$3.1M |
| Free cash flow | -$1.3M | -$2.2M | -$1.5M | -$1.4M | -$1.7M | -$2.5M | -$1.9M | -$3.1M |
| Gross margin | 15.8% | 0.0% | — | 0.0% | — | — | — | — |
| Operating margin | -3798.2% | -7192.9% | -2850.0% | -6102.4% | — | — | — | — |
| Net margin | -3763.2% | -7192.9% | -2875.6% | -6111.9% | — | — | — | — |
Company news
Jun 22, 2026
- 28d agoENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?stocktwits.com
- 28d agoEntera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosisfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Toledano Miranda Jayne· Chief Executive Officer | Award | 347,567 | $0.00 | $0.00 | filing |
| 2026-07-14 | Toledano Miranda Jayne· Chief Executive Officer | Award | 72,993 | $0.00 | $0.00 | filing |
| 2026-05-07 | Galitzer Hillel· Chief Operating Officer | Award | 72,993 | $0.00 | $0.00 | filing |
| 2026-05-07 | Yaacov-Garbeli Dana· Chief Financial Officer | Award | 58,394 | $0.00 | $0.00 | filing |
| 2026-05-07 | Burshtein Gregory· Chief of R&D | Award | 87,591 | $0.00 | $0.00 | filing |
| 2026-03-09 | Germano Geno J | Buy | 20,000 | $1.30 | $26,000.00 | filing |
| 2026-03-05 | Ellis Sean | Buy | 10,000 | $1.23 | $12,300.00 | filing |
| 2026-02-12 | Rubin Steven D | Buy | 5,000 | $1.49 | $7,450.00 | filing |
| 2026-02-10 | Germano Geno J | Buy | 20,000 | $1.49 | $29,800.00 | filing |
| 2026-02-10 | Taitel Haya | Buy | 7,500 | $1.48 | $11,100.00 | filing |
| 2026-02-09 | Ellis Sean | Buy | 18,000 | $1.24 | $22,320.00 | filing |
| 2026-02-09 | Rubin Steven D | Buy | 10,000 | $1.20 | $12,000.00 | filing |
| 2026-01-01 | OSTROV GERALD M | Award | 28,721 | $0.00 | $0.00 | filing |
| 2026-01-01 | Ellis Sean | Award | 25,371 | $0.00 | $0.00 | filing |
| 2026-01-01 | Malca Yonatan | Award | 30,157 | $0.00 | $0.00 | filing |
| 2026-01-01 | LIEBERMAN GERALD M | Award | 38,294 | $0.00 | $0.00 | filing |
| 2026-01-01 | Taitel Haya | Award | 26,329 | $0.00 | $0.00 | filing |
| 2025-12-29 | Toledano Miranda Jayne· Chief Executive Officer | Buy | 11,000 | $1.81 | $19,912.20 | filing |
| 2025-07-16 | Toledano Miranda Jayne· Chief Executive Officer | Award | 136,842 | $0.00 | $0.00 | filing |
| 2025-07-16 | Toledano Miranda Jayne· Chief Executive Officer | Award | 43,860 | $0.00 | $0.00 | filing |
| 2025-07-16 | Burshtein Gregory· Chief of R&D | Award | 26,316 | $0.00 | $0.00 | filing |
| 2025-07-16 | Yaacov-Garbeli Dana· Chief Financial Officer | Award | 26,316 | $0.00 | $0.00 | filing |
Latest 22 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.